Positive
New Resource Helps Patients Navigate HER2+ Gastroesophageal Cancer – Jazz Pharmaceuticals
Jazz Pharmaceuticals/LinkedIn

New Resource Helps Patients Navigate HER2+ Gastroesophageal Cancer – Jazz Pharmaceuticals

Jazz Pharmaceuticals, shared on LinkedIn:

“For patients facing a new HER2-positive gastroesophageal adenocarcinoma (GEA) diagnosis, navigating clinical details can feel overwhelming. In busy consultations, it can be hard to process biomarker results or remember what to ask.

Our HER2+ GEA Patient Discussion Guide helps patients partner with their care team. Download the guide and access additional patient and caregiver resources here.”

You can also read: FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

New Resource Helps Patients Navigate HER2+ Gastroesophageal Cancer - Jazz Pharmaceuticals

cancer cancer awareness cancer care cancer patient support Care Team gastroesophageal adenocarcinoma gastroesophageal cancer GEA HER2 HER2 positive cancer HER2-positive gastroesophageal adenocarcinoma HER2+ GEA Jazz Pharmaceuticals OncoDaily Oncology Patient Centered Care Patient Discussion Guide patient education Patient Empowerment patient resources patient support Patient-Caregiver Resources shared decision-making